University of California

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Darryl C Zeldin

Bruce D Hammock

Christophe H Morisseau

Deanna Kroetz

James K Liao

Perry J Blackshear

Deborah J Stumpo

Joan P Graves

The present disclosure relates to RFX4_v3 protein and nucleic acids encoding the RFX4_v3 protein. The present disclosure provides non-human transgenic animals with altered RFX4_v3 genes, and provides assays for the detection of RFX4_v3 and RFX4_v3 polymorphisms associated with disease states. The present disclosure additionally provides methods of determining a subjects' risk of developing congenital hydrocephalus, and treating or inhibiting its development.

Compositions and methods for diagnostics and therapeutics for hydrocephalus

Epoxyeicosatrienoic acids (EETs) are products of cytocrome P450 epoxygenases that have vasodilatory properties similar to endotheilum-derived hyperpolarizing factor (EDHF). The cytochrome P450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion molecule expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-&#x3ba;B and I&#x3ba;B kinase (IKK). The inhibitory effects of EETs were independent of their membrane hyporpolarizing effects suggesting that these molecules play an important non-vasodilatory role in vascular inflammation.

Anti-inflammatory actions of cytochrome P450 expoxygenase-derived eicosanoids

Inhibitors of epoxide hydrolases for the treatment of hypertension

Growing community of inventors

Chapel Hill, NC, United States of America

Darryl C Zeldin